Innoviva Inc. is an innovative pharmaceutical company, focusing primarily on managing royalty portfolios that originate from collaborations with external partners. This asset plays a significant role in the healthcare sector, specifically within the pharmaceuticals and biotechnology industries. The company is involved in the development and commercialization of products in the respiratory disease space, notably co-developing medicines that address chronic obstructive pulmonary disease (COPD) and asthma. Innoviva Inc.'s strategy revolves around optimizing the value of its intellectual property through strategic partnerships with major pharmaceutical players. By leveraging its royalty agreements, the company aims to maximize returns while minimizing direct operational risks associated with drug development. Founded in 1996 as Theravance, the firm transitioned to Innoviva Inc., illustrating a shift towards focusing on royalty management and investment in biopharmaceutical innovations. This positioning allows Innoviva to have a significant presence in the market, impacting the treatment approaches in the respiratory disease segment and contributing to the broader pharmaceutical and healthcare ecosystem."}